Literature DB >> 9820495

Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells.

D Matesic1, A Valujskikh, E Pearlman, A W Higgins, A C Gilliam, P S Heeger.   

Abstract

Allograft rejection has been associated with detection of the type 1 lymphokines, IFN-gamma and IL-2. The role of type 2 cytokines (IL-4 and IL-5) remains controversial, as is whether alloreactive CD4+ and CD8+ T cells behave similarly when exposed to type 2 cytokine-enhancing manipulations. We studied the characteristics of alloreactive CD4+ and CD8+ T cells before and after type 2 immune deviation induced by IL-4 plus anti-IFN-gamma Ab. Alloreactive T cells from naive mice were low in frequency, produced only IL-2, and were predominantly CD4+, while alloreactive T cells from allograft-primed mice were high in frequency, produced IFN-gamma, IL-2, and IL-4, and were predominantly CD8+. Type 2 immune deviation of allospecific CD4+ T cells resulted in IL-4 and IL-5 production without IFN-gamma, consistent with unipolar type 2 immunity. These T cells mediated delayed-type hypersensitivity, but not cytotoxicity. Under identical type 2 cytokine-inducing conditions, allospecific CD8+ T cells were primed to become IL-4, IL-5, and IFN-gamma producers, and exhibited cytotoxicity, but not classic delayed-type hypersensitivity. Adoptive transfer of either cell population into SCID recipients of allogeneic skin resulted in graft rejection, with stable allospecific type 2 cytokine production in vivo. Adoptive transfer of the IL-4/IL-5-producing CD4+ T cells, but not the CD8+ T cells, induced a distinct histopathology characterized by marked eosinophilic infiltration of the skin. We conclude that type 2 immune deviation has differential effects on CD4+ and CD8+ T cells and results in emergence of alternate effector mechanisms capable of destroying allografts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9820495

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Routes to allograft survival.

Authors:  J S Bromberg; B Murphy
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

2.  Antigen location contributes to the pathological features of a transplanted heart graft.

Authors:  Yifa Chen; Yilmaz Demir; Anna Valujskikh; Peter S Heeger
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

3.  Expanded nonhuman primate tregs exhibit a unique gene expression signature and potently downregulate alloimmune responses.

Authors:  A Anderson; C L Martens; R Hendrix; L L Stempora; W P Miller; K Hamby; M Russell; E Strobert; B R Blazar; T C Pearson; C P Larsen; L S Kean
Journal:  Am J Transplant       Date:  2008-09-17       Impact factor: 8.086

4.  Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection.

Authors:  Vasile Pavlov; Hugo Raedler; Shuguang Yuan; Staci Leisman; Wing-Hong Kwan; Peter N Lalli; M Edward Medof; Peter S Heeger
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

Review 5.  Deciphering the role of eosinophils in solid organ transplantation.

Authors:  Oscar Okwudiri Onyema; Yizhan Guo; Atsushi Hata; Daniel Kreisel; Andrew E Gelman; Elizabeth A Jacobsen; Alexander Sasha Krupnick
Journal:  Am J Transplant       Date:  2019-11-18       Impact factor: 8.086

6.  T cells in peripheral blood after gluten challenge in coeliac disease.

Authors:  R P Anderson; D A van Heel; J A Tye-Din; M Barnardo; M Salio; D P Jewell; A V S Hill
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

7.  Dual effects of the alloresponse by Th1 and Th2 cells on acute and chronic rejection of allotransplants.

Authors:  Ben M Illigens; Akira Yamada; Natalie Anosova; Victor M Dong; Mohamed H Sayegh; Gilles Benichou
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

8.  Reduced Satb1 expression predisposes CD4+ T conventional cells to Treg suppression and promotes transplant survival.

Authors:  Pawan K Gupta; Jennifer B Allocco; Jane M Fraipont; Michelle L McKeague; Peter Wang; Michael S Andrade; Christine McIntosh; Luqiu Chen; Ying Wang; Yan Li; Jorge Andrade; José R Conejo-Garcia; Anita S Chong; Maria-Luisa Alegre
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-26       Impact factor: 12.779

9.  CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.

Authors:  Francesca D'Addio; Takuya Ueno; Michael Clarkson; Baogong Zhu; Andrea Vergani; Gordon J Freeman; Mohamed H Sayegh; Mohammed Javeed I Ansari; Paolo Fiorina; Antje Habicht
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

10.  Innate immunity and resistance to tolerogenesis in allotransplantation.

Authors:  Gilles Benichou; Makoto Tonsho; Georges Tocco; Ognjenka Nadazdin; Joren C Madsen
Journal:  Front Immunol       Date:  2012-04-19       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.